The US Department of Commerce has left unresolved the exact circumstances in which the federal government can require a patent owner or licensee to share its patent rights with another party, but its suggestion that drug pricing is not likely to be a factor for pharma patents will surely drive further debate over the issue before regulations are implemented.
On 24 April, the Commerce Department's National Institute of Standards and Technology (NIST) issued a final Green Paper addressing the "march-in" provision of the Bayh-Dole Act of 1980, which allows the federal government to march in to require the contractor, assignee or exclusive licensee of an invention to
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?